IP Verse

Cancer Treatment Method - EP2124547

The patent EP2124547 was granted to Glaxosmithkline on Jun 18, 2025. The application was originally filed on Feb 15, 2008 under application number EP08729939A. The patent is currently recorded with a legal status of "The Patent Has Been Limited".

EP2124547

GLAXOSMITHKLINE
Application Number
EP08729939A
Filing Date
Feb 15, 2008
Status
The Patent Has Been Limited
May 16, 2025
Grant Date
Jun 18, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HGFDec 24, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (39) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS19970977217-
DESCRIPTIONWO2001US16863-
DESCRIPTIONEP1104674
DESCRIPTIONEP1207155
DESCRIPTIONEP1253142
DESCRIPTIONUS5342947
DESCRIPTIONUS5491237
DESCRIPTIONUS5559235
DESCRIPTIONUS5681835
DESCRIPTIONUS5877219
DESCRIPTIONUS6063923
DESCRIPTIONUS6207716
DESCRIPTIONUS6268391
DESCRIPTIONWO0107423
DESCRIPTIONWO0153267
DESCRIPTIONWO0189457
DESCRIPTIONWO0192211
DESCRIPTIONWO02059099
DESCRIPTIONWO02059100
DESCRIPTIONWO02062775
DESCRIPTIONWO03062233
DESCRIPTIONWO03098992
DESCRIPTIONWO2004029049
DESCRIPTIONWO2004096154
DESCRIPTIONWO2005118551
DESCRIPTIONWO2006047344
DESCRIPTIONWO2007062078
DESCRIPTIONWO2007106564
DESCRIPTIONWO9911262
EXAMINATIONEP1466912
EXAMINATIONUS5342947
INTERNATIONAL-SEARCH-REPORTUS2004053946
INTERNATIONAL-SEARCH-REPORTWO0192306
INTERNATIONAL-SEARCH-REPORTWO2006047344
OPPOSITIONWO0189457
OPPOSITIONWO03098992
SEARCHEP1207155
SEARCHUS2004019190
SEARCHWO2006047344

Non-Patent Literature (NPL) Citations (70) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ABRAHAM, R.T., CURRENT OPINION IN IMMUNOLOGY, (1996), vol. 8, no. 3, pages 412 - 8-
DESCRIPTION- ASHBY, M.N., CURRENT OPINION IN LIPIDOLOGY, (1998), vol. 9, no. 2, pages 99 - 102-
DESCRIPTION- BIOCHIM. BIOPHYS. ACTA, vol. 1423, no. 3, pages 19 - 30-
DESCRIPTION- BOLEN, J.B.; BRUGGE, J.S., ANNUAL REVIEW OF IMMUNOLOGY, (1997), vol. 15, pages 371 - 404-
DESCRIPTION- BREKKEN, R.A. ET AL., "Selective Inhibition of VEGFR2 Activity by a monoclonal Anti-VEGF antibody blocks tumor growth in mice", CANCER RES., (2000), vol. 60, pages 5117 - 5124, XP002340113-
DESCRIPTION- BRODT, P; SAMANI, A.; NAVAB, R., BIOCHEMICAL PHARMACOLOGY, (2000), vol. 60, pages 1101 - 1107-
DESCRIPTION- BRUNS CJ ET AL., CANCER RES., (2000), vol. 60, pages 2926 - 2935-
DESCRIPTION- CANMAN, C.E.; LIM, D.S., ONCOGENE, (1998), vol. 17, no. 25, pages 3301 - 3308-
DESCRIPTION- CHEN, J. ET AL., BLOOD, (1995), vol. 86, pages 4054 - 4062-
DESCRIPTION- CHEN Y; HU D; ELING DJ; ROBBINS J; KIPPS TJ., CANCER RES., (1998), vol. 58, pages 1965 - 1971-
DESCRIPTION- CWIRLA, S. E. ET AL., SCIENCE, (1997), vol. 276, page 1696-
DESCRIPTION- EINZIG, PROC. AM. SOC. CLIN. ONCOL., vol. 20, page 46-
DESCRIPTION- EZUMI, Y. ET AL., FEBS LETTERS, (1995), vol. 374, pages 48 - 52-
DESCRIPTION- FORASTIRE, SEM. ONCOL., (1990), vol. 20, page 56-
DESCRIPTION- GAUDUCHON ET AL., CLIN. CANCER RES., (2005), vol. 11, pages 2345 - 2354-
DESCRIPTION- HASEGAWA T. ET AL., INT. J. IMMUNOPHARM., (1996), vol. 18, pages 103 - 112-
DESCRIPTION- HOLMES ET AL., J. NAT. CANCER INST., (1991), vol. 83, page 1797-
DESCRIPTION- JACKSON, S.P., INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, (1997), vol. 29, no. 7, pages 935 - 8-
DESCRIPTION- KATH, JOHN C., EXP. OPIN. THER. PATENTS, (2000), vol. 10, no. 6, pages 803 - 818-
DESCRIPTION- KEARNS, C.M., SEMINARS IN ONCOLOGY, (1995), vol. 3, no. 6, pages 16 - 23-
DESCRIPTION- KITADA S ET AL., ANTISENSE RES. DEV., (1994), vol. 4, pages 71 - 79-
DESCRIPTION- KOJIMA, H. ET AL., THROMBOSIS & HAEMOSTASSIS, (1995), vol. 74, pages 1541 - 1545-
DESCRIPTION- KOMATSU ET AL., BLOOD, (1996), vol. 87, page 4552-
DESCRIPTION- KUMAR, J. BIOL, CHEM, (1981), vol. 256, pages 10435 - 10441-
DESCRIPTION- KUTER D. J., SEMINARS IN HEMATOLOGY, (2000), vol. 37, pages 41 - 9-
DESCRIPTION- LACKEY, K. ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2000), pages 223 - 226-
DESCRIPTION- LAMB ET AL., NUCLEIC ACIDS RESEARCH, (1995), vol. 23, pages 3283 - 3289-
DESCRIPTION- LAURENZ JC. ET AL., COMP. BIOCHEM. & PHVS. PART A. PHYSIOLOGY., (1997), vol. 116, pages 369 - 77-
DESCRIPTION- MARKMAN ET AL., YALE JOURNAL OF BIOLOGY AND MEDICINE, (1991), vol. 64, page 583-
DESCRIPTION- MARTINEZ-LACACI, L. ET AL., INT. J. CANCER, (2000), vol. 88, no. 1, pages 44 - 52-
DESCRIPTION- MASSAGUE, J.; WEIS-GARCIA, F., CANCER SURVEYS, (1996), vol. 27, pages 41 - 64-
DESCRIPTION- MCCABE ET AL., CANCER RES., (2006), vol. 66, pages 8109 - 8115-
DESCRIPTION- MCDONALD, AM. J. PED. HEMATOLOAV/ONCOLOAV, (1992), vol. 14, pages 8 - 21-
DESCRIPTION- MCGUIRE ET AL., ANN. INTEM, MED., (1989), vol. 111, page 273-
DESCRIPTION- METCALF NATURE, (1994), vol. 369, pages 519 - 520-
DESCRIPTION- "New trends in Natural Products Chemistry 1986", D. G. I. KINGSTON ET AL., Studies in Organic Chemistry, ELSEVIER, (1986), vol. 26, pages 219 - 235-
DESCRIPTION- PHILIP, P.A.; HARRIS, A.L., CANCER TREATMENT AND RESEARCH, (1995), vol. 78, pages 3 - 27-
DESCRIPTION- REILLY RT ET AL., CANCER RES., (2000), vol. 60, pages 3569 - 3576-
DESCRIPTION- ROSANIA ET AL., EXP. OPIN. THER. PATENTS, (2000), vol. 10, no. 2, pages 215 - 230-
DESCRIPTION- SCHAROVSKY, O.G.; ROZADOS, V.R.; GERVASONI, S.I.; MATAR, P., JOURNAL OF BIOMEDICAL SCIENCE, (2000), vol. 7, no. 4, pages 292 - 8-
DESCRIPTION- SCHIFF ET AL., NATURE, (1979), vol. 277, pages 665 - 667-
DESCRIPTION- SCHIFF ET AL., PROC. NATL, ACAD, SCI. USA, (1980), vol. 77, pages 1561 - 1565-
DESCRIPTION- SCHREIBER AB; WINKLER ME; DERYNCK R., SCIENCE, (1986), vol. 232, pages 1250 - 1253-
DESCRIPTION- SEIDEL ET AL., PROC. NATL. ACAD. SCI., USA, (1995), vol. 92, pages 3041 - 3045-
DESCRIPTION- SHAWVER ET AL., DDT, (199702), vol. 2, no. 2-
DESCRIPTION- SHIOTSU Y. ET AL., EXP. HEMAT., (1998), vol. 26, pages 1195 - 1201-
DESCRIPTION- SINH, S.; COREY, S.J., JOURNAL OF HEMATOTHERAPY AND STEM CELL RESEARCH, (1999), vol. 8, no. 5, pages 465 - 80-
DESCRIPTION- SMITHGALL, T.E., JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, (1995), vol. 34, no. 3, pages 125 - 32-
DESCRIPTION- "Tyrosine Kinase Signalling in Breast cancer:erbB Family Receptor Tyrosine Kniases", BREAST CANCER RES., (2000), vol. 2, no. 3, pages 176 - 183-
DESCRIPTION- VIGON ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 5640 - 5644-
DESCRIPTION- WANI ET AL., J. AM. CHEM, SOC., (1971), vol. 93, page 2325-
DESCRIPTION- WATER JS ET AL., J. CLIN. ONCOL., (2000), vol. 18, pages 1812 - 1823-
DESCRIPTION- WOO, NATURE, (1994), vol. 368, page 750-
DESCRIPTION- YAMAMOTO, T.; TAYA, S.; KAIBUCHI, K., JOURNAL OF BIOCHEMISTRY, (1999), vol. 126, no. 5, pages 799 - 803-
DESCRIPTION- YEN L ET AL., ONCOGENE, (2000), vol. 19, pages 3460 - 3469-
DESCRIPTION- ZHELEV ET AL., CANCER CHEMOTHER PHARMACOL, (2004), vol. 53, pages 267 - 275-
DESCRIPTION- ZHONG, H. ET AL., CANCER RES, (2000), vol. 60, no. 6, pages 1541 - 1545-
DESCRIPTION- GREEN, M.C. ET AL., "Monoclonal Antibody Therapy for Solid Tumors", CANCER TREAT. REV., (2000), vol. 26, no. 4, doi:doi:10.1053/ctrv.2000.0176, pages 269 - 286, XP009019784
OPPOSITION- "assessment report", European Medicines Agency (Application for Variation, (20150723), XP055657039-
OPPOSITION- "Clinical Trial NCT00102726", (20061115), URL: https://clinicaltrials.gov/ct2/history/NCT00102726?V_10=View#StudyPageTop, XP055542047-
OPPOSITION- Duffy et al., "Chapter 13 - The discovery of eltrombopag, an orally bioavailable TpoR agonist", Duffy et al., Metcalf et al., Target Validation in Drug Discovery, (20070000), pages 241 - 254, XP055541987-
OPPOSITION- ERIKSON-MILLER et al., "Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag", Leukemia Research, (20100000), vol. 34, no. 9, doi:10.1016/j.leukres.2010.02.005, ISSN 0145-2126, pages 1224 - 1231, XP027182205-
OPPOSITION- "FDA Approves New Indication for Promacta (eltrombopag) for Severe Aplastic Anemia", (20140826), drugs.com, URL: https://www.drugs.com/newdrugs/fda-approves-new-indication-promacta-eltrombopag-severe- aplastic-anemia-4077. html, XP055657036-
OPPOSITION- "FDA prescribing information highlights for Promacta", FDA, (20150800), page 1, XP055620814-
OPPOSITION- ., "New Therapy Significantly Increases Platelet Count", URL: https://hepcassoc.org/news/article140.html-
OPPOSITION- Philippa Redondo, "No clinical benefit of eltrombopag versus placebo in combination with induction chemotherapy in patients with acute myeloid leukemia", (20190205), AMLGlobalPortal, URL: https://amlglobalportal.com/medical-information/combination-of-eltrombopag-with-induction- chemotherapy-in-patients-with-acute-myeloid-leukemia, XP055657033-
OPPOSITION- MCHUTCHISON et al., "Efficacy and Safety of Eltrombopag, an Oral Platelet Growth Factor, in subjects with HCV associated Thrombocytopenia: Preliminary results from a Phase II Dose-Ranging Study", Journal of Hepatology, (20060400), vol. 44, no. suppl. 2, page S276, XP025054093
OPPOSITION- John G Mchutchison et al., "Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C", The New England Journal of Medicine, (20071129), vol. 357, no. 22, pages 2227 - 2236, XP055542014
OPPOSITION- ROTH et al., "Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation", Blood, (20120000), vol. 120, no. 2, doi:10.1182/blood-2011-12-399667, ISSN 0006-4971, pages 386 - 394, XP055228731
OPPOSITION- KUROKAWA et al., "The Eltrombopag antitumor effect on hepatocellular carcinoma", International Journal of Oncology, (20151100), vol. 47, no. 5, doi:10.3892/ijo.2015.3180, ISSN 1019-6439, pages 1696 - 1702, XP055620807

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents